Bococizumab HIV Evaluation (B-HIVE) Study: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of Bococizumab, a PCSK9 Inhibitor, in HIV-Infected Subjects

Trial Profile

Bococizumab HIV Evaluation (B-HIVE) Study: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of Bococizumab, a PCSK9 Inhibitor, in HIV-Infected Subjects

Discontinued
Phase of Trial: Phase III

Latest Information Update: 01 Feb 2017

At a glance

  • Drugs Bococizumab (Primary)
  • Indications Dyslipidaemias; Hyperlipidaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms B-HIVE
  • Most Recent Events

    • 01 Nov 2016 Status changed from recruiting to discontinued since the company has decided to discontinue the global clinical development of bococizumab, according to a Pfizer media release.
    • 09 Aug 2016 Planned End Date changed from 1 Dec 2016 to 1 Sep 2019.
    • 09 Aug 2016 Planned primary completion date changed from 1 May 2016 to 1 Apr 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top